BISPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS

Clinical trials for BISPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS explained in plain language.

Never miss a new study

Get alerted when new BISPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS trials appear

Sign up with your email to follow new studies for BISPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Swiss hospital tests 'Double-Target' immune therapy for tough blood cancers

Disease control Not yet recruiting

This early-stage trial is testing the safety of a new, locally-made CAR-T cell therapy designed to attack two targets (CD19 and CD20) on cancer cells. It is for adults with advanced B-cell leukemias or lymphomas who have relapsed after or cannot access standard treatments, includ…

Matched conditions: BISPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS

Phase: PHASE1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control

Last updated Mar 23, 2026 15:18 UTC

BISPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS

Get alerted when new BISPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS trials appear

Swiss hospital tests 'Double-Target' immune therapy for tough blood cancers